Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study - ScienceDirect

Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study - ScienceDirect

Comments

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News